PRESS RELEASE Algenex Announces GMP Certification Madrid, 19 April 2022 - Algenex, a leader in the production of alternative proteins, backed by Cleon Capital and Columbus Ventures, announces that...
PRESS RELEASE Algenex Announces Entry into the Food Technology Market Madrid, 21 March 2022 - Algenex, a leader in the production of alternative proteins, backed by Cleon Capital and Columbus...
La compañía biotecnológica española Algenex SL, respaldada por Cleon Capital y Colombus Ventures; y la línea de negocio de Fabricación de Equipos Originales (OEM, por sus siglas en inglés) de Werfen, acaban de renovar su acuerdo de licencia para la fabricación de productos de diagnósticos humanos in vitro. El acuerdo permitirá a Biokit el uso del sistema de expresión in vivo IBES® (ImprovedBaculovirusExpressionSystem) y la plataforma de expresión mediada por vectores de baculovirus que utiliza insectos como biorreactores naturales de un solo uso para la producción de proteínas recombinantes, CrisBio®. Ambas son patentes de Algenex.
Madrid and Barcelona (Spain)18November, 2021 – Algenex SL, a biotech company backed by Cleon Capital and Columbus Ventures delivering disruptive technologies for recombinant biologics production, and Biokit Research and Development S.L.U, part of the Werfen Group, have renewed a license agreement which provides Biokit with the non-exclusive use of Algenex’ platforms, IBES® (Improved Baculovirus Expression System) and CrisBio® for the production of human in vitro diagnostics.
La compañía biotecnológica española Algenex SL ha sido reconocida como la mejor empresa europea en los Premios de Salud Animal 2021 (Animal Health Awards) que otorga, cada año, IHS Markit Agribusiness, la mayor plataforma de información global del panorama empresarial actual. Este premio ha sido concedido por el destacado grado de innovación que Algenex está aportando en el ámbito de la salud animal, tal como ha señalado Joseph Harvey, responsable de esta área en IHS Markit.
Algenex SL, a biotech company backed by Cleon Capital and Columbus Ventures delivering disruptive technologies for recombinant biologics production, and Global Dx Ltd, a company dedicated to improving the quality of animal care by facilitating accurate diagnosis for veterinarians worldwide, today announce the adoption of Herdscreen® ASFV Antibody Test by a major Spanish producer of pig-derived food and meat.
Madrid (Spain) and Menstrie (UK) 28October, 2021 – Algenex SL, a biotech company backed by Cleon Capital and Columbus Ventures delivering disruptive technologies for recombinant biologics production, and Global Dx Ltd, a company dedicated to improving the quality of animal care by facilitating accurate diagnosis for veterinarians worldwide, today announce the adoption of Herdscreen® ASFV Antibody Test by a major Spanish producer of pig-derived food and meat.
Algenex SL, a biotech company delivering disruptive technologies for recombinant biologics production, has announced its entry into the biocomponents market at the Biospain 2021 conference in Pamplona. Algenex intends to provide a high quality, lower cost alternative to traditional methods through its automated and bioreactor-free expression platform, Cris- Bio®, which harnesses the power of insects as natural single-use bioreactors.
The EU and the United Kingdom validate Algenex's Spanish CrisBio® technology, with the approval of the vaccine against the viral haemorrhagic disease of the rabbit developed with this platform
The European Comission has granted marketing approval to a rabiit hemorrhagic disease virus (RHVD) from Italian business Fatro. The vaccine incorporates CrisBio technology developed by Spain´s Algenex.